

## Clinical Trials Summary for out of hours Important Reference

<b>Acronym study title</b>	<b>TRIDENT</b> – Tumour Treating Field (TTF) concomitant with radiation therapy and temozolomide for newly diagnosed glioblastoma
<b>Study Details</b>	Patients are randomized to have TTF either with both chemoradiation and adjuvant chemotherapy or only with adjuvant chemotherapy. TTF will be delivered through an external device on the scalp which apply electric field through the brain
<b>Principal Investigator PI Sub PI's</b>	Principal Investigator - Mr Isaac Phang, Neurosurgery Sub Investigator- Dr Erica Beaumont, clinical oncology Sub Investigator - Dr Tai-Chung Lam, clinical oncology
<b>Research Nurse Team</b>	Sonia Raj Senior Research Nurse, Terrie-Louise Cromie Research Practitioner, Allan Brown Research Nurse, Helen Cross Research Nurse
<b>Drug therapy</b>	No experimental drug therapy  TTF is an FDA approved device which is applied through pieces of transducer array on the scalp. The array was connected to an external battery for electric field delivery
<b>In the event that a patient calls this hotline for advise</b>	TTF was well tolerated in most patients. The most common side effect is the scalp irritation which may cause itchiness, redness, pain or discharge. This should be readily treatable with hydrocortisone cream or topical antibiotics.  Previous studies showed that TTF patients were not at higher risk of seizure.  <b>TTF Contact Sue Brabbon Mob 07442 895390</b>